Generali's nine-month earnings figures have exceeded UBS's forecasts and consensus estimates, indicating a stronger performance than expected.
Despite this positive report, UBS has maintained its "Sell" rating for Generali and set a target price of 21 euros. Investors should carefully consider the implications of this rating and target price in light of the recent financial results.